Physician profile
Ranjit R Pullarkat
NPI 1972558377
$6,812.88
in general payments reported to CMS, 2019-2025
12 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,922 · 2020: $105 · 2021: $64.03 · 2022: $27.56 · 2024: $487 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,765.23 | 2019-2022 | |
| Boston Scientific Corporation | $436.97 | 2024 | Spyglass Discover, Axios |
| Davol INC. | $184.16 | 2019 | |
| Acumed LLC | $117.61 | 2024-2025 | Ribloc, Biobridge, Acutie II |
| Ethicon US, LLC | $117.50 | 2025 | Echelon Circular, Echelon; Endopath, Surgicel Nu-Knit |
| W. L. Gore & Associates, INC. | $39.91 | 2020 | |
| Zimmer Biomet Holdings, INC. | $36.13 | 2020 | |
| Endogastric Solutions, INC | $28.69 | 2020 | |
| Abbott Laboratories | $23.87 | 2021 | |
| Allergan, INC. | $23.25 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.65 | 2024 | Andexxa |
| Novo Nordisk INC | $16.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjit Pullarkat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.